Significados de metastatic castration en inglés

We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

The drug is already approved to treat metastatic castration-resistant prostate cancer.

Conclusions: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.

A more reliable tumor marker is needed as a prognostic indicator in metastatic castration-resistant prostate cancer.

This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.

Background: The optimal sequence of life-extending therapies in metastatic castration-resistant prostate cancer (mCRPC) is unknown.

Background: There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC).

On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.

Assessment of treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases.

Objectives: The independent prognostic effect of comorbidities on outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) is unclear.

Introduction: Radium-223 dichloride is the first alpha-particle emitting therapeutic agent approved by FDA and EMA for bone metastatic castration-resistant prostate cancer.

Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastatic castration-resistant prostate cancer.

Purpose: Increases in androgen receptor (AR) copy number (CN) can be detected in plasma DNA when patients develop metastatic castration-resistant prostate cancer.

Conclusion: Patients with metastatic castration-resistant prostate cancer can be dichotomized by a plasma AR CN cut point of 1.92.

Conclusion: TP53 GOF mutations may provide a valuable pathway to delineate metastatic castration-resistant prostate cancer TP53 mutations into therapeutic categories.

The new approval is for patients with metastatic castration-sensitive prostate cancer, while the drug was earlier approved for non metastatic and metastatic castration-resistant prostate cancer.